Madrigal Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Madrigal Pharmaceuticals 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MDGL

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. 

CEO
William J. Sibold
CEOWilliam J. Sibold
Employees
915
Employees915
Headquarters
West Conshohocken, Pennsylvania
HeadquartersWest Conshohocken, Pennsylvania
Founded
2000
Founded2000
Employees
915
Employees915

MDGL Key Statistics

Market cap
11.13B
Market cap11.13B
Price-Earnings ratio
-38.85
Price-Earnings ratio-38.85
Dividend yield
Dividend yield
Average volume
268.79K
Average volume268.79K
High today
$507.35
High today$507.35
Low today
$479.00
Low today$479.00
Open price
$495.74
Open price$495.74
Volume
83.12K
Volume83.12K
52 Week high
$615.00
52 Week high$615.00
52 Week low
$265.20
52 Week low$265.20

Stock Snapshot

The current Madrigal Pharmaceuticals(MDGL) stock price is $482.76, with a market capitalization of 11.13B. The stock trades at a price-to-earnings (P/E) ratio of -38.85.

During the trading session on 2026-06-01, Madrigal Pharmaceuticals(MDGL) shares reached a daily high of $507.35 and a low of $479.00. At a current price of $482.76, the stock is +0.8% higher than the low and still -4.8% under the high.

Trading activity shows a volume of 83.12K, compared to an average daily volume of 268.79K.

The stock's 52-week range extends from a low of $265.20 to a high of $615.00.

The stock's 52-week range extends from a low of $265.20 to a high of $615.00.

MDGL News

Simply Wall St 4d
A Look At Madrigal Pharmaceuticals Valuation After New Phase 3 And Real World Rezdiffra MASH Data - simplywall.st

...

A Look At Madrigal Pharmaceuticals Valuation After New Phase 3 And Real World Rezdiffra MASH Data - simplywall.st
Simply Wall St 7d
Did New Noninvasive Rezdiffra Data at EASL 2026 Just Shift Madrigal Pharmaceuticals' Investment Narrative?

Madrigal Pharmaceuticals recently announced that multiple new data sets from its Rezdiffra development and real‑world evidence programs were presented at the EA...

Did New Noninvasive Rezdiffra Data at EASL 2026 Just Shift Madrigal Pharmaceuticals' Investment Narrative?

Analyst ratings

89%

of 18 ratings
Buy
88.9%
Hold
11.1%
Sell
0%

People also own

Based on the portfolios of people who own MDGL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.